CFB and non-Hodgkin lymphoma: In contrast, a univariate logistic regression on evaluable anti-Omicron BA.1 antibody response described a significant direct association with anti-SARS-CoV-2 vaccines (odds ratio [OR] 7.2; 95% confidential interval [CI] 1.10–57.00; P = 0.05), while an inverse trend was observed for anti-CD20 monoclonal antibody therapy administered in the last 12 months (OR 0.26; 95%CI 0.07–0.88; P = 0.03) and diagnosis of NHL (OR 0.29; 95%CI 0.04–0.95; P = 0.04) (Table 5; dependent variable, presence of neutralizing antibody response against Omicron BA.1 variant).